Shares of Checkpoint Therapeutics Inc. (CKPT) reached a 52-week high of $4.33 during intraday trading yesterday, as the company gears up for a key regulatory catalyst in the coming weeks.
The company's lead investigational product Cosibelimab, an anti-programmed death ligand-1 ("PD-L1") antibody, is under FDA review, with a decision due on December 28, 2024.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.